Guard Therapeutics today announces that the company has received a grant from the Chinese Patent Office (China National Intellectual Property Administration) for its patent application no. 201780018244.4 that protects the company's biological investigational drug RMC-035 as a product.

The approved patent is officially announced as patent no. CN 108779157 B and will be valid until 2037. The approval means that the company's patent portfolio and thus the commercial potential for RMC-035 are further strengthened.
 
"The positive news from the Chinese Patent Office means that Guard Therapeutics has now received patent protection for RMC-035 in all major pharmaceutical markets around the world, which also include the US, EU and Japan. China is considered to be an important market for acute kidney injuries, and this provides the best possible conditions for a future commercialization of our investigational drug", says Tobias Agervald, CEO of Guard Therapeutics. 

For further information, please contact:

Tobias Agervald, CEO
Telephone: +46 8 670 65 51
E-mail: info@guardtherapeutics.com 

About Guard Therapeutics

Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm.

Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, ca@skmg.se.

This information is information that Guard Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-01-09 15:05 CET.

Attachments

Guard Therapeutics receives patent approval for RMC-035 in China

© Modular Finance, source Nordic Press Releases